Tianjin Ringpu Bio-Technology Co (300119) Fair Value & Analysis

Healthcare · CN · Market cap 7.3B CNY

Analysis

Tianjin Ringpu Bio-Technology Co (300119) currently trades at ¥15.19, while our model-based Fair Value estimate is ¥18.96 — implying the stock looks roughly 24.8% undervalued today. We read business quality at 86/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sale of veterinary raw materials, pharmaceutical preparation, functional additives, and veterinary biological products. The company provides vaccines, chemical drugs, traditional Chinese medicines; feed additives, including pigs, chickens, waterfowl, cattle, sheep and pet medicines, and vaccines; and poultry, waterfowl, livestock, rumination, pets, washing and disinfection, active pharmaceutical ingredients product series. It also offers diagnosis and treatment services, such as epidemic diagnosis and testing, animal drug evaluation, and veterinary socialization. The company was founded in 1998 and is headquartered in Tianjin, China.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.